This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Agios shareholders approve sale of oncology busine...

Agios shareholders approve sale of oncology business to Servier

Read time: 1 mins
Published:26th Mar 2021
Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, LLC, an independent global pharmaceutical company. Approximately 99.9% of the shares voted at the Special Meeting, representing approximately 90% of the outstanding shares entitled to vote, were voted in favor of the transaction. Agios will file the final vote results, as certified by the independent Inspector of Election, on a Form 8-K with the U.S. Securities and Exchange Commission. Agios expects the close of the transaction to occur around March 31, 2021, subject to the satisfaction of customary closing conditions.
Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.